Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mercuri

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.
European Journal of Heart Failure|November 29, 2019
Left atrial structure and function and the risk of death or heart failure in atrial fibrillationRiccardo M Inciardi, Robert P Giugliano, Brian Claggett, et al.
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Thrombosis and Haemostasis|November 18, 2016
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxabanJack E Ansell, Sasha H Bakhru, Bryan E Laulicht, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Coronary artery calcium outperforms carotid artery intima-media thickness as a noninvasive index of prevalent coronary artery stenosisJames G Terry, J Jeffrey Carr, Rong Tang, et al.
Circulation. Arrhythmia and Electrophysiology|January 13, 2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Mark S Link, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.
American Heart Journal|January 25, 2021
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyJoris R de Groot, Christian T Ruff, Sabina A Murphy, et al.
The Lancet. Haematology|August 2, 2016
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trialGary E Raskob, Nick van Es, Annelise Segers, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
European Heart Journal. Acute Cardiovascular Care|July 25, 2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48Thomas A Zelniker, Christian T Ruff, Stephen D Wiviott, et al.
European Journal of Heart Failure|November 29, 2019
Left atrial structure and function and the risk of death or heart failure in atrial fibrillationRiccardo M Inciardi, Robert P Giugliano, Brian Claggett, et al.
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Thrombosis and Haemostasis|November 18, 2016
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxabanJack E Ansell, Sasha H Bakhru, Bryan E Laulicht, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 11, 2005
Coronary artery calcium outperforms carotid artery intima-media thickness as a noninvasive index of prevalent coronary artery stenosisJames G Terry, J Jeffrey Carr, Rong Tang, et al.
Circulation. Arrhythmia and Electrophysiology|January 13, 2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Mark S Link, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.
American Heart Journal|January 25, 2021
Edoxaban versus warfarin in patients with atrial fibrillation in relation to the risk of stroke: A secondary analysis of the ENGAGE AF-TIMI 48 studyJoris R de Groot, Christian T Ruff, Sabina A Murphy, et al.
The Lancet. Haematology|August 2, 2016
Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trialGary E Raskob, Nick van Es, Annelise Segers, et al.
Pageof 10